Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study

BACKGROUND: Programmed death-1 (PD-1) inhibitors have been approved and are currently widely used to treat lung cancer patients. However, comparative data on the adverse events (AEs) associated with different PD-1 inhibitors are very limited. METHODS: Patients with histologically confirmed lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xiaowei, Tao, Gang, Sun, Song, Jin, Xiangni, Chen, Yanning, Zhang, Yiwen, Sun, Jiao, Huang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908189/
https://www.ncbi.nlm.nih.gov/pubmed/35280395
http://dx.doi.org/10.21037/atm-21-6899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908189/
https://www.ncbi.nlm.nih.gov/pubmed/35280395
http://dx.doi.org/10.21037/atm-21-6899

Ejemplares similares